NVEC INVESTOR ALERT: Investigation of NVE Corporation Announced by Holzer & Holzer, LLC

NVE reported significant quarter-over-quarter decreases in fiscal Q2 2027 revenue, product sales, gross profit, and diluted EPS; it attributed lower product sales to a short-term inventory adjustment at one large medical-device customer and a 95% decline in defense product sales. The company’s stock price dropped after the disclosure. Holzer & Holzer is investigating whether NVE complied with federal securities laws.

Analysis

The core risk is whether the reported weakness is timing noise or evidence of unstable end demand. A large medical-device customer’s inventory correction can defer orders without changing ultimate consumption; however, combined with a sharp defense-sales decline, it leaves two distinct demand channels needing recovery. If sales remain weak, lower gross profit could amplify earnings pressure through operating leverage, but the available facts do not establish the size or persistence of that effect.

Near term, the securities-law investigation is not evidence of a violation and may add headline volatility without changing fundamentals. Over the next 1–3 months, the key catalyst is management’s next update on customer inventory normalization, defense orders, and product-level sales. Over 6–18 months, repeated volatility in either channel would raise questions about revenue visibility and the durability of the company’s earnings base. The contrarian point: the sequential decline may be overinterpreted as a structural break, but a quick rebound should not be assumed from the company’s characterization of one customer adjustment as short term.

Key Decisions for Investors

• Avoid treating the investigation announcement alone as a short catalyst; it does not establish wrongdoing or quantify financial exposure.
• Keep NVEC on a results-driven watchlist rather than initiating a directional position solely on this report. Before taking risk, verify the quarterly product-sales and gross-profit figures, customer concentration, order backlog, and management’s outlook.
• A bullish entry becomes more credible if the next report shows medical-customer orders normalizing and defense sales recovering; falsify that thesis if product sales or gross profit weaken again, or management indicates the inventory correction is extending.
• For existing holders, size exposure for continued earnings volatility: the combined weakness across two end markets raises downside risk if it persists, while a documented rebound could unwind some of the post-results pessimism.